ANI PHARMACEUTICALS INC (ANIP) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
ANIP currently has 21.5M outstanding shares. with minimal authorized share overhang for future dilution. The company has diluted shareholders by 19.9% over the past 2 years through share issuances.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 08, 2026 |
10-Q filing | 21.5M shares outstanding |
22M | 0 |
| Nov 07, 2025 |
10-Q filing | 21.1M shares outstanding |
21M | 0 |
| Aug 08, 2025 |
10-Q filing | 20.3M shares outstanding |
20M | 0 |
| May 09, 2025 |
10-Q filing | 20.0M shares outstanding |
20M | 0 |
| Feb 28, 2025 |
10-K filing | 21.8M shares outstanding |
22M | 0 |
| Nov 08, 2024 |
10-Q filing | 19.4M shares outstanding |
19M | 0 |
| Aug 13, 2024 |
8-K filing: ANI Pharmaceuticals issued $316.25 million principal amount of 2.25% Convertible Senior Notes due 2029, with an initial conversion rate of 13.4929 shares per $1,000 principal amount of notes, potentially resulting in the issuance of up to 5,547,246 shares of common stock upon conversion. |
19M | 0 |
| Aug 06, 2024 |
10-Q filing | 19.3M shares outstanding |
19M | 0 |
| May 10, 2024 |
10-Q filing | 19.4M shares outstanding |
19M | 0 |
| Feb 29, 2024 |
10-K filing | 21.1M shares outstanding |
21M | 0 |
| Nov 08, 2023 |
10-Q filing | 19.1M shares outstanding |
19M | 0 |
| Aug 09, 2023 |
10-Q filing | 20.3M shares outstanding |
20M | 0 |
| May 16, 2023 |
8-K filing: ANI Pharmaceuticals, Inc. completed the sale of 2,183,545 shares of its common stock at a public offering price of $39.50 per share, receiving gross proceeds of approximately $86.25 million. ($86.25M proceeds) |
11K | 3.1M |
| May 12, 2023 |
8-K filing: ANI Pharmaceuticals, Inc. priced its underwritten public offering and agreed to issue and sell 1,898,735 shares of its common stock at a price of $39.50 per share, for gross proceeds of approximately $75 million. ($75.0M proceeds) |
11K | 3.1M |
| May 08, 2023 |
10-Q filing | 0.0M shares outstanding |
11K | 3.1M |
| Mar 09, 2023 |
10-K filing | 0.0M shares outstanding |
11K | 3.1M |
| Nov 09, 2022 |
10-Q filing | 0.0M shares outstanding |
11K | 3.1M |
| Aug 08, 2022 |
10-Q filing | 0.0M shares outstanding |
11K | 3.1M |
| May 10, 2022 |
10-Q filing | 0.0M shares outstanding |
11K | 3.1M |
| Mar 15, 2022 |
10-K filing | 0.0M shares outstanding |
11K | 3.1M |
| Dec 17, 2021 |
S-3 filing: This S-3 filing relates to the resale or other disposition from time to time of up to 3,069,555 shares of common stock by selling stockholders. |
11K | 3.1M |
| Nov 26, 2021 |
8-K filing: The company completed a private placement with Ampersand 2020 Limited Partnership, issuing 25,000 shares of Series A Convertible Preferred Stock for $25 million. ($25.0M proceeds) |
11K | 0 |
| Nov 04, 2021 |
8-K filing: ANI Pharmaceuticals, Inc. entered into an underwriting agreement to issue and sell up to 1,725,000 shares of common stock at a public offering price of $50.00 per share. |
11K | 0 |
| Nov 01, 2021 |
10-Q filing | 0.0M shares outstanding |
11K | 0 |
| Aug 06, 2021 |
10-Q filing | 0.0M shares outstanding |
11K | 0 |
| May 07, 2021 |
10-Q filing | 0.0M shares outstanding |
11K | 0 |
| Mar 11, 2021 |
10-K filing | 0.0M shares outstanding |
11K | 0 |
| Mar 09, 2021 |
8-K filing: ANI Pharmaceuticals, Inc. entered into a merger agreement with Novitium Pharma LLC, involving cash, stock, and potential earn-out payments, and also entered into an Equity Commitment and Investment Agreement with Ampersand 2020 Limited Partnership for the issuance of Series A Convertible Preferred Stock. ($25.0M proceeds) |
11K | 0 |
| Nov 05, 2020 |
10-Q filing | 0.0M shares outstanding |
11K | 0 |
| Aug 06, 2020 |
10-Q filing | 0.0M shares outstanding |
11K | 0 |
| Jul 09, 2020 |
S-3 filing: This S-3 filing registers an offering for up to $350,000,000 of any combination of common stock, preferred stock, debt securities, warrants, units, and rights. |
11K | 0 |
| May 07, 2020 |
10-Q filing | 0.0M shares outstanding |
11K | 0 |
| Feb 27, 2020 |
10-K filing | 0.0M shares outstanding |
11K | 0 |